MERUS NV (MRUS) Stock Price, Forecast & Analysis
USA - NASDAQ:MRUS - NL0011606264 - Common Stock
MRUS Key Statistics, Chart & Performance
The current stock price of MRUS is 95.17 USD. In the past month the price increased by 0.61%. In the past year, price increased by 74.61%.
MRUS Latest News, Press Relases and Analysis
MRUS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.23 | 387.80B | ||
| AMGN | AMGEN INC | 14.6 | 171.86B | ||
| GILD | GILEAD SCIENCES INC | 14.69 | 149.26B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.51 | 104.64B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.34 | 68.41B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 846.43 | 56.58B | ||
| INSM | INSMED INC | N/A | 38.71B | ||
| NTRA | NATERA INC | N/A | 25.57B | ||
| BIIB | BIOGEN INC | 9.36 | 22.97B | ||
| INCY | INCYTE CORP | 16.3 | 20.43B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.95 | 20.24B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 36.01 | 14.93B |
Related stock screener links
About MRUS
Company Profile
Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. The company is headquartered in Utrecht, Utrecht and currently employs 260 full-time employees. The company went IPO on 2016-05-19. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The firm operates in the Netherlands and United States.
Company Info
MERUS NV
Yalelaan 62
Utrecht UTRECHT 3584 NL
CEO: Sven A. Lundberg
Employees: 260
Phone: 310302538800
MERUS NV / MRUS FAQ
Can you describe the business of MERUS NV?
Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. The company is headquartered in Utrecht, Utrecht and currently employs 260 full-time employees. The company went IPO on 2016-05-19. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The firm operates in the Netherlands and United States.
Can you provide the latest stock price for MERUS NV?
The current stock price of MRUS is 95.17 USD. The price increased by 0.01% in the last trading session.
What is the dividend status of MERUS NV?
MRUS does not pay a dividend.
How is the ChartMill rating for MERUS NV?
MRUS has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the Price/Earnings (PE) ratio of MERUS NV (MRUS)?
MERUS NV (MRUS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.34).
Would investing in MERUS NV be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on MRUS.
MRUS Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to MRUS. When comparing the yearly performance of all stocks, MRUS is one of the better performing stocks in the market, outperforming 94.39% of all stocks.
MRUS Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to MRUS. MRUS has a great financial health rating, but its profitability evaluates not so good.
MRUS Financial Highlights
Over the last trailing twelve months MRUS reported a non-GAAP Earnings per Share(EPS) of -5.34. The EPS decreased by -36.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -39.33% | ||
| ROE | -45.8% | ||
| Debt/Equity | 0 |
MRUS Forecast & Estimates
23 analysts have analysed MRUS and the average price target is 99.48 USD. This implies a price increase of 4.53% is expected in the next year compared to the current price of 95.17.
For the next year, analysts expect an EPS growth of -78.63% and a revenue growth 40.37% for MRUS